Sep 22, 2025, 06:33
Antiphospholipid Syndrome (APS) in Pregnancy – Key Takeaways
Dr. Mukesh, Assistant Professor of Clinical Immunology and Rheumatology at King George’s Medical University (KGMU), posted on X:
”Antiphospholipid Syndrome (APS) in Pregnancy – Key Takeaways
- APS affects 0.5% of the population but is a major cause of recurrent pregnancy loss (RPL), preeclampsia and FGR.
- Pathogenesis: “Two-hit model” → aPL antibodies trigger endothelial/placental dysfunction → thrombosis + insufficiency.
- Lupus anticoagulant (LA) = strongest predictor of poor outcomes.
- Standard of care: Low-dose aspirin (LDA) + LMWH → boosts live birth rates.
- Hydroxychloroquine (HCQ) reduces preterm birth and improves placental health in high-risk cases.
- Refractory APS? → Novel options: TNF-α inhibitors, complement blockers (eculizumab), nitric oxide modulators, statins.
- APS + SLE overlap = compounded risks → needs aggressive, multidisciplinary management.
- CAPS (catastrophic APS) = rare but lethal; pregnancy can trigger it (mortality ~36%).
- New 2023 ACR/EULAR criteria improve APS classification and risk stratification in pregnancy.
Bottom line: Early diagnosis, tailored therapy, and multidisciplinary care = better outcomes for mom and baby.”
Read the full review here.
Title: Antiphospholipid syndrome in pregnancy: a comprehensive literature review
Authors: Viorela Romina Murvai, Radu Galiș, Anca Panaitescu, Casandra Maria Radu, Timea Claudia Ghitea, Paula Trif, Miruna Onița-Avram, Alexandra Alina Vesa, Anca Huniadi

Stay updated with Hemostasis Today.
Alexandra Alina Vesa
Anca Huniadi
Anca Panaitescu
Antiphospholipid Syndrome
APS
Aspirin
BioMed Central
BMC
Casandra Maria Radu
Catastrophic APS
Health
Hematology
Hemostasis
Hemostasis Today
Heparin
Hydroxychloroquine
Immunology
in Pregnancy
King George's Medical University (KGMU)
LMWH
Low-Molecular-Weight Heparin
Lupus anticoagulant (LA)
Medicine
Miruna Onița-Avram
Mukesh
Paula Trif
Pregnancy
Radu Galiș
Recurrent Pregnancy Loss (RPL)
Rheumatology
thrombosis
Timea Claudia Ghitea
Viorela Romina Murvai
-
Nov 14, 2025, 11:58Marilena Vrana: Can Public-only Blood Collection Systems Meet the Growing Patient Need for PDMs?
-
Nov 14, 2025, 11:48Cedric Hermans Shares the 1st Illustrated Review Dedicated to Hemophilia B
-
Nov 14, 2025, 10:28Valance Washington: Proud to Share Our Lab’s Latest Publication in Platelets Journal
-
Nov 14, 2025, 10:18Sripal Bangalore and Ajay Kirtane on TUXEDO-2 Comparison Focusing on Diabetic Patients
-
Nov 14, 2025, 10:11Ashley Lawrenson on Her Coagulation Journey Using Automation With the HemoCell and HemoHub
-
Nov 14, 2025, 10:05Kingsley Wheaton: A Year Ago, Omni Was an Idea – Today, It’s a Movement!
-
Nov 14, 2025, 09:58Rucha Patil Takes The National DHR-ICMR Gold Award for Best Technology
-
Nov 14, 2025, 09:48Caitlin Raymond on ”The Plasma Chasers”
-
Nov 14, 2025, 09:42Erin VanDyke on Why They Do In-person Site Visits for NBCA Centers of Excellence Designation!
